The Taiwan Food and Drug Administration has initiated a safety review of contraceptive products containing the active ingredients desogestrel and etonogestrel. This regulatory action follows a recent alert issued by the European Medicines Agency, which identified a potential correlation between the long-term administration of these specific hormones and a slight elevation in the risk of developing meningioma. Taiwan's health regulators are currently evaluating the clinical data to determine if additional safety measures or updated warnings are necessary for patients using these medications within the country. The assessment aims to ensure that medical practitioners and the public are fully informed about the potential health implications associated with extended usage of these particular birth control formulations.
Source : Focus Taiwan
